Do analysts recommend ALEC or GNTA?

Alector currently has a consensus price target of $3.63, indicating a potential upside of 98.09%. Given Alector's stronger consensus rating and higher possible upside, research analysts clearly believe Alector is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ALEC or GNTA?

Genenta Science has lower revenue, but higher earnings than Alector. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alector $21.05M 9.65 -$142.93M -$1.19 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Do analysts prefer GNTA or PRQR?

ProQR Therapeutics has a consensus price target of $7.25, indicating a potential upside of 283.60%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ProQR Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has better valuation & earnings, GNTA or PRQR?

Genenta Science has higher earnings, but lower revenue than ProQR Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A ProQR Therapeutics $17.99M 11.07 -$47.73M -$0.50 N/A

Do analysts rate GNTA or ADAG?

Adagene has a consensus price target of $8.00, indicating a potential upside of 101.01%. Given Adagene's stronger consensus rating and higher possible upside, analysts clearly believe Adagene is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adagene 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, GNTA or ADAG?

Genenta Science has higher earnings, but lower revenue than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Adagene $7.67M 24.59 -$17.61M N/A N/A

Is GNTA or ADAG more profitable?

Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A Adagene N/A N/A N/A

Do analysts prefer GNTA or DTIL?

Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 364.03%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts plainly believe Precision BioSciences is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Precision BioSciences 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has better earnings and valuation, GNTA or DTIL?

Genenta Science has higher earnings, but lower revenue than Precision BioSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Precision BioSciences $34.26M 5.23 -$45.72M -$3.67 N/A

Do analysts prefer GNTA or DERM?

Journey Medical has a consensus price target of $13.00, indicating a potential upside of 94.03%. Given Journey Medical's stronger consensus rating and higher probable upside, analysts clearly believe Journey Medical is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Journey Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings & valuation, GNTA or DERM?

Genenta Science has higher earnings, but lower revenue than Journey Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Journey Medical $61.86M 2.98 -$11.43M -$0.37 N/A

Genenta Science (GNTA) Competitors

$1.84 -0.08 (-4.17%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$1.84 +0.00 (+0.22%)

As of 06/23/2026 07:34 PM Eastern

Compare

GNTA vs. ALEC, PRQR, ADAG, DTIL, and DERM

Should you buy Genenta Science stock or one of its competitors? MarketBeat compares Genenta Science with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genenta Science include Alector (ALEC), ProQR Therapeutics (PRQR), Adagene (ADAG), Precision BioSciences (DTIL), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

How does Genenta Science compare to Alector?

Alector (NASDAQ:ALEC) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Genenta Science has a net margin of 0.00% compared to Alector's net margin of -680.83%. Genenta Science's return on equity of 0.00% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Genenta Science	N/A	N/A	N/A

Genenta Science has lower revenue, but higher earnings than Alector.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.65	-$142.93M	-$1.19	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

Alector currently has a consensus price target of $3.63, indicating a potential upside of 98.09%. Given Alector's stronger consensus rating and higher possible upside, research analysts clearly believe Alector is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Alector had 3 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Alector and 0 mentions for Genenta Science. Alector's average media sentiment score of 1.02 beat Genenta Science's score of 0.00 indicating that Alector is being referred to more favorably in the media.

Company	Overall Sentiment
Alector	Positive
Genenta Science	Neutral

Alector has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

85.8% of Alector shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 8.3% of Alector shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Alector beats Genenta Science on 7 of the 13 factors compared between the two stocks.

How does Genenta Science compare to ProQR Therapeutics?

Genenta Science (NASDAQ:GNTA) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Genenta Science has higher earnings, but lower revenue than ProQR Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
ProQR Therapeutics	$17.99M	11.07	-$47.73M	-$0.50	N/A

Genenta Science has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

ProQR Therapeutics has a consensus price target of $7.25, indicating a potential upside of 283.60%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Genenta Science has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Genenta Science's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

In the previous week, Genenta Science's average media sentiment score of 0.00 equaled ProQR Therapeutics'average media sentiment score.

Company	Overall Sentiment
Genenta Science	Neutral
ProQR Therapeutics	Neutral

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Genenta Science beats ProQR Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Genenta Science compare to Adagene?

Genenta Science (NASDAQ:GNTA) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Genenta Science has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Adagene has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Adagene	N/A	N/A	N/A

In the previous week, Adagene had 1 more articles in the media than Genenta Science. MarketBeat recorded 1 mentions for Adagene and 0 mentions for Genenta Science. Adagene's average media sentiment score of 0.36 beat Genenta Science's score of 0.00 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
Genenta Science	Neutral
Adagene	Neutral

Adagene has a consensus price target of $8.00, indicating a potential upside of 101.01%. Given Adagene's stronger consensus rating and higher possible upside, analysts clearly believe Adagene is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Genenta Science has higher earnings, but lower revenue than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Adagene	$7.67M	24.59	-$17.61M	N/A	N/A

Summary

Adagene beats Genenta Science on 7 of the 11 factors compared between the two stocks.

How does Genenta Science compare to Precision BioSciences?

Genenta Science (NASDAQ:GNTA) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Genenta Science has higher earnings, but lower revenue than Precision BioSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Precision BioSciences	$34.26M	5.23	-$45.72M	-$3.67	N/A

Genenta Science has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 364.03%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts plainly believe Precision BioSciences is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 2.7% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Precision BioSciences' average media sentiment score of 1.34 beat Genenta Science's score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Genenta Science	Neutral
Precision BioSciences	Positive

Genenta Science has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Genenta Science's return on equity of 0.00% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Precision BioSciences	-96.73%	-85.37%	-37.34%

Summary

Precision BioSciences beats Genenta Science on 7 of the 12 factors compared between the two stocks.

How does Genenta Science compare to Journey Medical?

Genenta Science (NASDAQ:GNTA) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Journey Medical has a consensus price target of $13.00, indicating a potential upside of 94.03%. Given Journey Medical's stronger consensus rating and higher probable upside, analysts clearly believe Journey Medical is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Genenta Science's average media sentiment score of 0.00 equaled Journey Medical'saverage media sentiment score.

Company	Overall Sentiment
Genenta Science	Neutral
Journey Medical	Neutral

Genenta Science has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Genenta Science's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Journey Medical	-14.82%	-35.57%	-10.88%

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genenta Science has higher earnings, but lower revenue than Journey Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Journey Medical	$61.86M	2.98	-$11.43M	-$0.37	N/A

Genenta Science has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Summary

Genenta Science beats Journey Medical on 6 of the 11 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNTA vs. The Competition

Export

Metric	Genenta Science	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$45.29M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	N/A	19.75	24.92	23.98
Price / Sales	N/A	330.90	528.23	109.07
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.43	8.29	10.79	6.50
Net Income	-$7.39M	$23.85M	$3.56B	$336.88M
7 Day Performance	N/A	2.87%	1.00%	-0.14%
1 Month Performance	217.24%	2.19%	0.42%	0.77%
1 Year Performance	-40.26%	55.48%	29.70%	28.49%

Genenta Science Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNTA Genenta Science	0.2381 of 5 stars	$1.84 -4.2%	N/A	-39.9%	$45.29M	N/A	N/A	7	Gap Down
ALEC Alector	3.0805 of 5 stars	$1.58 +2.3%	$3.63 +130.2%	+33.1%	$174.86M	$18.42M	N/A	270	Positive News
PRQR ProQR Therapeutics	2.1541 of 5 stars	$1.66 +8.9%	$7.25 +338.1%	-3.1%	$174.37M	$13.42M	N/A	180
ADAG Adagene	2.5132 of 5 stars	$3.68 +5.0%	$8.00 +117.2%	+108.9%	$173.31M	$7.67M	N/A	260	Gap Down
DTIL Precision BioSciences	2.6719 of 5 stars	$6.71 +6.3%	$32.25 +380.6%	+53.4%	$173.13M	$45.07M	N/A	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNTA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genenta Science (GNTA) Competitors

GNTA vs. ALEC, PRQR, ADAG, DTIL, and DERM

How does Genenta Science compare to Alector?

Summary

How does Genenta Science compare to ProQR Therapeutics?

Summary

How does Genenta Science compare to Adagene?

Summary

How does Genenta Science compare to Precision BioSciences?

Summary

How does Genenta Science compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA vs. The Competition

Genenta Science Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genenta Science (GNTA) Competitors

GNTA vs. ALEC, PRQR, ADAG, DTIL, and DERM

How does Genenta Science compare to Alector?

Is ALEC or GNTA more profitable?

Which has preferable valuation & earnings, ALEC or GNTA?

Do analysts recommend ALEC or GNTA?

Does the media favor ALEC or GNTA?

Which has more volatility & risk, ALEC or GNTA?

Do insiders & institutionals have more ownership in ALEC or GNTA?

Summary

How does Genenta Science compare to ProQR Therapeutics?

Which has better valuation & earnings, GNTA or PRQR?

Which has more volatility and risk, GNTA or PRQR?

Do analysts prefer GNTA or PRQR?

Is GNTA or PRQR more profitable?

Does the media prefer GNTA or PRQR?

Do insiders and institutionals believe in GNTA or PRQR?

Summary

How does Genenta Science compare to Adagene?

Do institutionals & insiders have more ownership in GNTA or ADAG?

Which has more volatility and risk, GNTA or ADAG?

Is GNTA or ADAG more profitable?

Does the media prefer GNTA or ADAG?

Do analysts rate GNTA or ADAG?

Which has higher valuation & earnings, GNTA or ADAG?

Summary

How does Genenta Science compare to Precision BioSciences?

Which has better earnings and valuation, GNTA or DTIL?

Which has more volatility & risk, GNTA or DTIL?

Do analysts prefer GNTA or DTIL?

Do institutionals and insiders hold more shares of GNTA or DTIL?

Does the media refer more to GNTA or DTIL?

Is GNTA or DTIL more profitable?

Summary

How does Genenta Science compare to Journey Medical?

Do analysts prefer GNTA or DERM?

Does the media refer more to GNTA or DERM?

Is GNTA or DERM more profitable?

Do insiders and institutionals have more ownership in GNTA or DERM?

Which has stronger earnings & valuation, GNTA or DERM?

Which has more risk and volatility, GNTA or DERM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA vs. The Competition

Genenta Science Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools